可溶性Fas水平与乳腺疾病的关系

Relationships between soluble Fas levels and breast diseases

目的 :探讨血清可溶性 Fas(s Fas)水平的变化与乳腺疾病发生发展的相关性。方法 :采用 EL ISA方法检测 2 2 6例健康女性 ,2 0例复发性乳腺癌患者 ,81例原发性乳腺癌患者 ,2 2例乳腺良性疾病患者血清 s Fas水平。结果 :健康人群血清 s Fas水平随年龄增加而递增 ;原发性乳腺癌、复发性乳腺癌、良性乳腺疾病患者血清 s Fas水平 (分别为 0 .815、 1.5 10及 0 .6 6 4 ng· L- 1 )与正常人群 (0 .5 80 ng· L- 1 )比较差异具有显著性 (P<0 .0 5 ) ;原发乳腺癌患者术前、术后 2周 s Fas水平分别为 0 .815和 0 .6 2 0 ng· L- 1 ,两者比较差异具有显著性 (P<0 .0 5 ) ,良性乳腺疾病患者术前、术后 2周 s Fas水平分别为 0 .6 6 4和 0 .6 10 ng· L- 1 ,两者比较差异无显著性 (P>0 .0 5 ) ;原发乳腺癌患者 s Fas表达水平随疾病 TNM分期增高而增高 ,差异具有显著性 (P<0 .0 5 ) ,而其表达水平与雌激素受体 (ER)、孕激素受体 (PR)、局部淋巴结转移等其他临床参数差异无显著性 (P>0 .0 5 )。结论 :乳腺癌患者血清的 s Fas水平可作为乳腺疾病进展及其预后的判断指标之一。

Objective To explore the correlations of the changes of soluble Fas(sFas) levels with pathogenesis of breast diseases.Methods The serum sFas levels in 226 healthy women, 20 patients with recurrent breast cancer, 81 patients with primary breast cancer and 22 patients with benign breast diseases were detected by enzyme-link immunosorbent assay. Results In the healthy group,sFas level increased with age. The mean sFas levels in primary and recurrent cancer patients were 0.815 and 1.510 ng·L~ -1,respectively,they were higer than those in healthy controls and benign breast cancer patients (0.580 and 0. 664 ng·L~ -1,P<0.05). The sFas levels in patients with primary cancer before surgery and two weeks after surgery were 0.815 and 0.620 ng·L~ -1,respectively, the difference was significant (P<0.05). Ths sFas levels in primary cancer patients increased with tumor stages, the difference was significant (P<0.05), but had no correlation with estrogen receptor (ER), progestogen receptor (PR), and local lymphatic metastasis (P>0.05).Conclusion The serum sFas level in patents with breast cancer may be used as a index to judge the development and prognosis of breast cancer.